Additional content — Strontium ranelate (Protos) for postmenopausal osteoporosis: Differences between trial populations used for indirect comparisons between strontium and alendronateAdditional content — Strontium ranelate (Protos) for postmenopausal osteoporosis: Differences between trial populations used for indirect comparisons between strontium and alendronate

Published 2007-11-01 00:00:00

This page contains additional information about the article Strontium ranelate (Protos) for postmenopausal osteoporosis, published in NPS RADAR, November 2007.

Women enrolled in TROPOS probably had a higher risk of fracture than those in FIT-2 because of the mixture of primary and secondary prevention populations, and the fact that they were older and had lower average BMD (see Table 1). In TROPOS, 55% had a previous fracture, however, only 71% of the whole population were X-rayed for vertebral fracture, hence the exact proportion is unknown. These factors may explain why the absolute risk of fracture differs between TROPOS and FIT-2, as seen by comparing the placebo fracture event rates* (6.4% strontium; 2.2% alendronate). Though not identical, women in SOTI and FIT-1 showed more similarity in baseline fracture risk (see Table 2).14,16

* The validity of an indirect comparison depends on the included trials being similar (assuming each trial is internally valid) because the drug's absolute treatment effects (defined by the absolute risk reduction or number needed to treat) are influenced by baseline risk.

Table 1: Key characteristics of the TROPOS13 and FIT-215 trials (used for primary prevention comparison)

TROPOS FIT-2 (primary prevention)
Baseline risk
  • Femoral neck BMD < 0.60 g/cm2
  • 55% of women had a previous fracture (vertebral or non-vertebral) confirmed by X-ray
  • Mean femoral neck BMD 0.59 g/cm2
  • No previous radiographic vertebral fracture confirmed by X-ray
  • 35% had a history of postmenopausal fracture
Vertebral X-ray before randomising No Yes
Number of women 4932 4432
Completed follow-up 3320 (67%) 4134 (93%)
Mean age 77 years 68 years
Study centres 11 European countries and Australia 11 metropolitan areas of the United States
Intervention Strontium (either 2 g once daily or 1 g twice daily) versus placebo for 3 years. Alendronate 5 mg daily for 2 years then 10 mg daily versus placebo for 4 years
Primary outcome New non-vertebral fracture (excluding skull, face, finger, toe and coccyx) as diagnosed by a physician. One or more clinical fractures — pre-specified as vertebral, non-vertebral, hip, wrist and 'other' (excluding face or skull) as diagnosed by a physician.
Secondary outcomes Non-vertebral fractures by site — specified during the study as hip, wrist, pelvis–sacrum, rib–sternum, clavicle, humerus

Study not powered for these outcomes.		 Vertebral fractures diagnosed by X-ray.

Study not powered for this outcome.

TROPOS = Treatment of Peripheral Osteoporosis study13

FIT-2 = Fracture Intervention Trial15

Table 2: Key characteristics of the SOTI14 and FIT-116 trials (used for secondary prevention comparison)

SOTI FIT-1 (secondary prevention)
Baseline risk
  • Mean femoral neck BMD 0.59 g/cm2
  • All had vertebral fracture at baseline (confirmed by X-ray)

In addition to 1 baseline vertebral fracture:

  • Mean of 2 previous vertebral fractures
  • 33% had a previous non-vertebral fracture
  • Mean femoral neck BMD 0.57 g/cm2
  • All had vertebral fracture at baseline (confirmed by X-ray)

In addition to 1 baseline vertebral fracture:

  • 31% had multiple vertebral fractures
  • 57% had a history of postmenopausal fracture
  • About 30% had maternal history of fracture and previous falls.
Number of women 1442 2027
Completed follow-up 1260 (87%) 1946 (96%)
Mean age 70 years 71 years
Study centres 11 European countries and Australia 11 metropolitan areas of the United States
Intervention Strontium (either 2 g once daily or 1 g twice daily) versus placebo for 3 years. Alendronate 5 mg daily for 2 years then 10 mg daily versus placebo for 3 years
Primary outcome New radiographic or clinical vertebral fracture New radiographic vertebral fractures
Secondary outcomes Non-vertebral fractures (excluding skull, face, finger, toe and coccyx) confirmed by X-ray or hospital report

Study not powered for this outcome.		 Any symptomatic vertebral or non-vertebral fracture confirmed by X-ray or bone scan

Study powered for this outcome.

SOTI = Spinal Osteoporosis Therapeutic Intervention study14

FIT-1 = Fracture Intervention Trial16

References

References for this article are found on the page Strontium ranelate (Protos) for postmenopausal osteoporosis, from NPS RADAR November 2007.

RSS FeedRSS feed

Date published: 2007-11-01 00:00:00

Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.

References to brands should not be taken as an endorsement by NPS.